Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Acerta Pharma BV
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia
• Establish the safety and the MTD of orally administered acalabrutinib in subjects with CLL/SLL • Determine the PK of orally administered acalabrutinib and identification of its major metabolite
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell Lymphoma Estudio para ver los efectos de ACP-196 ( el fármaco del estudio) en pacientes con linfoma de células del manto
To determine the activity of ACP-196 in subjects with relapsed or refractory MCL as measured primarily by response rate. In addition, activity of ACP-169 will be assessed by duration of response, prog...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Clinical trial to compare standard of care treatment: Nab-Paclitaxel/Gemcitabine alone or in combination with ACP-196 in patients with previously untreated Metastatic Pancreatic Cancer
To evaluate the efficacy of ACP-196 and nab-paclitaxel/gemcitabine based on ORR in subjects with metastatic pancreatic cancer using standard response criteria
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma
To evaluate the efficacy of acalabrutinib (ACP-196) in combination with bendamustine and rituximab (BR) compared with placebo in combination with BR based on Independent Review Committee (IRC) asses...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B), based on IRC assessment of PFS per IWCLL 2008 cr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Clinical trial to compare Acalabrutinib (ACP-196) versus investigator's choice standard treatment with Bendamustine/Rituximab or Idelalisib/Rituximab alone in patients with with Relapsed or Refractory Chronic Lymphocytic Leukemia
To evaluate the efficacy of acalabrutinib monotherapy (Arm A) compared with idelalisib/rituximab or bendamustine/rituximab (Arm B) based on Independent Review Committee (IRC) assessment of progression...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Acerta Pharma BV
MAJ Il y a 4 ans
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
To check the efficacy of ACP-196 in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations